U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06813365) titled 'Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)' on Dec. 23, 2024.
Brief Summary: This study is designed to evaluate safety and antitumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations. This is the first time the drug is tested in human.
Study Start Date: June 12, 2024
Study Type: INTERVENTIONAL
Condition:
Nonsmall-cell Lung Cancer
Intervention:
DRUG: DZD6008
Daily dose of DZD6008
Recruitment Status: RECRUITING
Sponsor: Dizal Pharmaceuticals
Published by HT Digital Content Services with permission from Health Daily Digest....